Yood MU, Lafata JE, Koro C, Wells KE, Pladevall-Vila M. Time to pharmacotherapy change in response to elevated HbA(1c) test results. Curr Med Res Opin. 2006 Aug;22(8):1567-74.
Evans C, Katz N, Simon L, Bombardier C, West C, Robbins J, Copley-Merriman K, Coombs J. Development and preliminary validation of a responder index for patients with chronic low back pain. J Pain. 2006 Apr;7(4 (Supplement)):S84. doi: 10.1016/j.jpain.2006.01.341
Portenoy R, ID Pain Steering Committee, McLeod LD. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22(8):1555-65.
Jensen MP, Martin SA, Cheung R. The Meaning of pain relief in a clinical trial. J Pain. 2005 Jun 1;6:400-6.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X
Dubrey SW, Gnanasakthy A, Stein WK, Song JG, Hardman T, Hynd J, Noble MI. Enoximone in chronic stable angina: a double-blind placebo-controlled cross-over trial. J Cardiovasc Pharmacol. 1994 Apr;23(4):532-8.